+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Angioedema Treatment Market by Drugs Type, Route of Administration, End-User - Global Forecast 2025-2030- Product Image
Angioedema Treatment Market by Drugs Type, Route of Administration, End-User - Global Forecast 2025-2030- Product Image
Sale

Angioedema Treatment Market by Drugs Type, Route of Administration, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904682
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Angioedema Treatment Market grew from USD 4.69 billion in 2023 to USD 5.50 billion in 2024. It is expected to continue growing at a CAGR of 17.28%, reaching USD 14.32 billion by 2030.

Angioedema treatment refers to the management and alleviation of swelling in various body parts, primarily in the face, lips, throat, limbs, and gastrointestinal tract, caused by fluid leakage from blood vessels. The necessity for effective angioedema treatment arises due to its potential to cause life-threatening symptoms, such as airway obstruction. Common applications include chronic hereditary angioedema and allergic reactions, where treatments range from preventive medications, acute rescue therapies, to lifestyle and dietary adjustments. The end-use scope encompasses hospitals, specialty clinics, and homecare settings, reflecting diverse patient needs and healthcare delivery models.

Market insights indicate that key growth factors include the increasing prevalence of angioedema, advancements in biopharmaceuticals, and rising awareness of hereditary angioedema. Additionally, the approval and commercialization of novel drugs such as monoclonal antibodies provide significant growth opportunities. However, challenges include high treatment costs, misdiagnosis, and limited access to advanced therapies in certain regions. Potential opportunities lie in developing cost-effective biosimilars and expanding telehealth services, capitalizing on the growing demand for personalized medicine and remote patient monitoring. Recommendations to harness these opportunities include strategic partnerships with biotech firms, investing in advanced diagnostics, and expanding geographic reach by targeting emerging markets.

Limitations affecting market growth involve regulatory hurdles and the need for specialized expertise in treating hereditary cases. Further challenges are posed by competition from established brands and the slow adaptation of innovative treatments by healthcare practitioners. Areas ripe for innovation include gene therapy, improved delivery mechanisms for existing treatments, and development of comprehensive patient management platforms integrating genetic profiling. Research in these domains could lead to breakthroughs offering competitive advantages and significant market differentiation. The angioedema treatment market presents a complex landscape characterized by a mix of high-growth potential and inherent challenges, requiring focused innovation and strategic planning.

Understanding Market Dynamics in the Angioedema Treatment Market

The Angioedema Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing cases of hereditary angioedema (HAE)
    • Growing initiatives for improving awareness levels among the population
    • Rising incidence of disease-related genetic mutations
  • Market Restraints
    • Misdiagnosis of angioedema
  • Market Opportunities
    • Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
    • Development of advance therapeutics for hereditary angioedema disorders treatment
  • Market Challenges
    • High cost of the drugs used for treatment

Exploring Porter’s Five Forces for the Angioedema Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Angioedema Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Angioedema Treatment Market

External macro-environmental factors deeply influence the performance of the Angioedema Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Angioedema Treatment Market

The Angioedema Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Angioedema Treatment Market

The Angioedema Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Angioedema Treatment Market

The Angioedema Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drugs Type
    • C1 Esterase Inhibitor
      • Berinert
      • Cinryze
      • Haegarda
      • Ruconest
    • Kallikrein Inhibitor
      • Kalbitor
    • Selective Bradykinin B2 Receptor Antagonist
      • Firazyr
  • Route of Administration
    • Injections
    • Oral
  • End-User
    • Clinics
    • Hospitals
    • Research Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing cases of hereditary angioedema (HAE)
5.1.1.2. Growing initiatives for improving awareness levels among the population
5.1.1.3. Rising incidence of disease-related genetic mutations
5.1.2. Restraints
5.1.2.1. Misdiagnosis of angioedema
5.1.3. Opportunities
5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
5.1.4. Challenges
5.1.4.1. High cost of the drugs used for treatment
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Angioedema Treatment Market, by Drugs Type
6.1. Introduction
6.2. C1 Esterase Inhibitor
6.2.1. Berinert
6.2.2. Cinryze
6.2.3. Haegarda
6.2.4. Ruconest
6.3. Kallikrein Inhibitor
6.3.1. Kalbitor
6.4. Selective Bradykinin B2 Receptor Antagonist
6.4.1. Firazyr
7. Angioedema Treatment Market, by Route of Administration
7.1. Introduction
7.2. Injections
7.3. Oral
8. Angioedema Treatment Market, by End-User
8.1. Introduction
8.2. Clinics
8.3. Hospitals
8.4. Research Organizations
9. Americas Angioedema Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Angioedema Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Angioedema Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BERINERT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY CINRYZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HAEGARDA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RUCONEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY FIRAZYR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 82. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 88. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 97. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 100. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 133. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 136. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 158. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 161. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 167. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 206. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 209. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 212. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 215. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 278. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Angioedema Treatment Market, which are profiled in this report, include:
  • Adverum Biotechnologies, Inc.
  • AMBOSS GmbH
  • Apotex Corp.
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cipla USA Inc.
  • CSL Behring GmbH
  • Fresenius Kabi USA, LLC
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Lecturio GmbH
  • Merck & Co., Inc.
  • Pharming Group N.V.
  • Sanofi-Aventis Groupe S.A.
  • Slayback Pharma LLC
  • Takeda Pharmaceutical Company Limited
  • Viropharma Biologics LLC

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.32 Billion
Compound Annual Growth Rate17.2%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Global Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Forecast 2024-2030 - Product Image

Global Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Forecast 2024-2030

  • Report
  • 190 Pages
  • Global
From
Hereditary Angioedema Therapeutics Global Market Report 2024 - Product Image

Hereditary Angioedema Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Hereditary Angioedema Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Hereditary Angioedema Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 180 Pages
  • Global
From
Plasma Protease C1-Inhibitor Treatment - Global Strategic Business Report - Product Image

Plasma Protease C1-Inhibitor Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Global Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region - Product Image

Global Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.